Endocrinology and Metabolism

Volume 36(2); April 2021

In Memoriam

Miscellaneous
In Memoriam: Remembering Professor Hun-Ki Min (1928–2021): Young Min Cho; Endocrinol Metab. 2021;36(2):207-208. Published online April 20, 2021; DOI: https://doi.org/10.3803/EnM.2021.204

2,519 View
141 Download

PDF PubReader ePub Crossref - TDM

Review Articles

Obesity and Metabolism
Food Preferences and Obesity: Sara Spinelli, Erminio Monteleone; Endocrinol Metab. 2021;36(2):209-219. Published online April 19, 2021; DOI: https://doi.org/10.3803/EnM.2021.105

4,335 View
243 Download
15 Citations

Abstract PDF PubReader ePub Crossref - TDM

Obesity is a multifactorial disease with several potential causes that remain incompletely understood. Recent changes in the environment, which has become increasingly obesogenic, have been found to interact with individual factors. Evidence of the role of taste responsiveness and food preference in obesity has been reported, pointing to a lower taste sensitivity and a higher preference and intake of fat and, to a lesser extent, sweet foods in obese people. Studies in the last decades have also suggested that individual differences in the neurophysiology of food reward may lead to overeating, contributing to obesity. However, further studies are needed to confirm these findings. In fact, only a limited number of studies has been conducted on large samples, and several studies were conducted only on women. Larger balanced studies in terms of sex/gender and age are required in order to control the confounding effect of these variables. As many factors are intertwined in obesity, a multidisciplinary approach is needed. This will allow a better understanding of taste alteration and food behaviours in obese people in order to design more effective strategies to promote healthier eating and to prevent obesity and the related chronic disease risks.

Citations

Citations to this article as recorded by

Sex Differences in Effects of Mood, Eating-Related Behaviors, and BMI on Food Appeal and Desire to Eat: A Cross-Sectional Survey Study
Kristina T. Legget, Marc-Andre Cornier, Lauren Sarabia, Eve M. Delao, Susan K. Mikulich-Gilbertson, Crystal Natvig, Christina Erpelding, Tessa Mitchell, Allison Hild, Eugene Kronberg, Jason R. Tregellas
Nutrients.2023; 15(3): 762. CrossRef
Estimation of Free Sugars in the Filipino Food Composition Table and Evaluation of Population-Level Intake
Fabio Mainardi, Vanessa Caroline Campos, Richard Gaston Côté, Nele Kristin Silber, Roko Plestina, Imelda Angeles-Agdeppa
Nutrients.2023; 15(6): 1343. CrossRef
Genetic Obesity in Pregnant Ay Mice Does Not Affect Susceptibility to Obesity and Food Choice in Offspring
Elena Makarova, Anastasia Dubinina, Elena Denisova, Antonina Kazantseva
International Journal of Molecular Sciences.2023; 24(6): 5610. CrossRef
How Food Choices Impact College Going Students' Health in Urban Settings
Nikita Yadav, Ms. Rhitika Sharma, Ms. Divyanshi Kapoor, Dr. Payal Mahajan
International Journal of Scientific Research in Science and Technology.2023; : 774. CrossRef
Mediators of the association between maternal body mass index and breastfeeding duration in 3 international cohorts
Madeline Keyes, Chloe Andrews, Vishal Midya, Paula Carrasco, Mònica Guxens, Alba Jimeno-Romero, Mario Murcia, Cristina Rodriguez-Dehli, Dora Romaguera, Loreto Santa-Maria, Marina Vafeiadi, Lida Chatzi, Emily Oken, Martine Vrijheid, Damaskini Valvi, Sarbat
The American Journal of Clinical Nutrition.2023;[Epub] CrossRef
Taste of Fat and Obesity: Different Hypotheses and Our Point of View
Laurent Brondel, Didier Quilliot, Thomas Mouillot, Naim Akhtar Khan, Philip Bastable, Vincent Boggio, Corinne Leloup, Luc Pénicaud
Nutrients.2022; 14(3): 555. CrossRef
Long-Term Consumption of a Sugar-Sweetened Soft Drink in Combination with a Western-Type Diet Is Associated with Morphological and Molecular Changes of Taste Markers Independent of Body Weight Development in Mice
Barbara Lieder, Jozef Čonka, Agnes T. Reiner, Victoria Zabel, Dominik Ameur, Mark M. Somoza, Katarína Šebeková, Peter Celec, Veronika Somoza
Nutrients.2022; 14(3): 594. CrossRef
Phenotyping of Drosophila Melanogaster—A Nutritional Perspective
Virginia Eickelberg, Kai Lüersen, Stefanie Staats, Gerald Rimbach
Biomolecules.2022; 12(2): 221. CrossRef
Consumer Expectation of Flavored Water Function, Sensory Quality, and Sugar Reduction, and the Impact of Demographic Variables and Woman Consumer Segment
Uijeong An, Xiaofen Du, Wanyi Wang
Foods.2022; 11(10): 1434. CrossRef
Sex as an independent variable in the measurement of satiation: a retrospective cohort study
Maria D. Hurtado, Lizeth Cifuentes, Alejandro Campos, Alan De La Rosa, Ekta Kapoor, Stephanie S. Faubion, Donald D. Hensrud, Michael Camilleri, Andres Acosta
International Journal of Obesity.2022; 46(12): 2156. CrossRef
Associations between Overweight and Obesity and Common Mental Disorders and Eating Behaviors of Adult Women
Ana Clara Justino Valencio, Andressa Bueno Antunes, Lilian Fonseca, Julia Araujo, Maria Clara Goyer Silva, Marcia Costa, Juliana Gomes e Silva Czermainski, Carolina Böettge Rosa, Chaline Caren Coghetto, Randhall Bruce Carteri
Obesities.2022; 2(4): 350. CrossRef
Appetitive Motivation and Associated Neurobiology Change Differentially across the Life Course of Mouse Offspring Exposed to Peri- and Postnatal High Fat Feeding
Laura Contu, Christopher J. Heath, Cheryl A. Hawkes
Nutrients.2022; 14(23): 5161. CrossRef
Toward a Better Understanding of Diet–Taste Relations
Beverly J Tepper
The Journal of Nutrition.2021; 151(9): 2503. CrossRef
The Same Metabolic Response to FGF21 Administration in Male and Female Obese Mice Is Accompanied by Sex-Specific Changes in Adipose Tissue Gene Expression
Elena Makarova, Antonina Kazantseva, Anastasia Dubinina, Tatiana Jakovleva, Natalia Balybina, Konstantin Baranov, Nadezhda Bazhan
International Journal of Molecular Sciences.2021; 22(19): 10561. CrossRef
Influence of leptin administration to pregnant female mice on obesity development, taste preferences, and gene expression in the liver and muscles of their male and female offspring
E. I. Denisova, M. M. Savinkova, E. N. Makarova
Vavilov Journal of Genetics and Breeding.2021; 25(6): 669. CrossRef

Obesity and Metabolism
Digital Therapeutics for Obesity and Eating-Related Problems: Meelim Kim, Hyung Jin Choi; Endocrinol Metab. 2021;36(2):220-228. Published online March 24, 2021; DOI: https://doi.org/10.3803/EnM.2021.107

6,829 View
349 Download
6 Citations

Abstract PDF PubReader ePub Crossref - TDM

In recent years, digital technologies have rapidly advanced and are being applied to remedy medical problems. These technologies allow us to monitor and manage our physical and mental health in our daily lives. Since lifestyle modification is the cornerstone of the management of obesity and eating behavior problems, digital therapeutics (DTx) represent a powerful and easily accessible treatment modality. This review discusses the critical issues to consider for enhancing the efficacy of DTx in future development initiatives. To competently adapt and expand public access to DTx, it is important for various stakeholders, including health professionals, patients, and guardians, to collaborate with other industry partners and policy-makers in the ecosystem.

Citations

Citations to this article as recorded by

Digital therapeutics from bench to bedside
Changwon Wang, Chungkeun Lee, Hangsik Shin
npj Digital Medicine.2023;[Epub] CrossRef
Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease
Run Zhou, Yunpeng Gu, Binbin Zhang, Tingting Kong, Wei Zhang, Jie Li, Junping Shi
Clinical and Translational Gastroenterology.2023; 14(4): e00575. CrossRef
Comprehensive traditional East Asian medicine treatment strategy for obesity considering the therapeutic effects and adverse events
Hongmin Chu, Byungsoo Kang, Bo-Young Youn, Kwan-il Kim, Jinbong Park, Jungtae Leem
Medicine.2022; 101(6): e28673. CrossRef
Clinical Evaluation of Digital Therapeutics: Present and Future
Ki Young Huh, Jaeseong Oh, SeungHwan Lee, Kyung-Sang Yu
Healthcare Informatics Research.2022; 28(3): 188. CrossRef
Health-Related Indicators Measured Using Earable Devices: Systematic Review
Jin-Young Choi, Seonghee Jeon, Hana Kim, Jaeyoung Ha, Gyeong-suk Jeon, Jeong Lee, Sung-il Cho
JMIR mHealth and uHealth.2022; 10(11): e36696. CrossRef
Clinical Efficacy of a Digital Intervention for Patients with Atopic Dermatitis: a Prospective Single-Center Study
Sigrídur Lára Gudmundsdóttir, Tommaso Ballarini, María L. Ámundadóttir, Judit Mészáros, Jenna H. Eysteinsdóttir, Ragna H. Thorleifsdóttir, Sigrídur K. Hrafnkelsdóttir, Heida B. Bragadóttir, Saemundur Oddsson, Jonathan I. Silverberg
Dermatology and Therapy.2022; 12(11): 2601. CrossRef

Obesity and Metabolism
Dopaminergic Control of the Feeding Circuit: Ja-Hyun Baik; Endocrinol Metab. 2021;36(2):229-239. Published online April 6, 2021; DOI: https://doi.org/10.3803/EnM.2021.979

7,200 View
382 Download
8 Citations

Abstract PDF PubReader ePub Crossref - TDM

There is increasing evidence demonstrating that reward-related motivational food intake is closely connected with the brain’s homeostatic system of energy balance and that this interaction might be important in the integrative control of feeding behavior. Dopamine regulates motivational behavior, including feeding behaviors, and the dopamine reward system is recognized as the most prominent system that controls appetite and motivational and emotional drives for food. It appears that the dopamine system exerts a critical role in the control of feeding behavior not only by the reward-related circuit, but also by contributing to the homeostatic circuit of food intake, suggesting that dopamine plays an integrative role across the converging circuitry of control of food intake by linking energy state-associated signals to reward-related behaviors. This review will cover and discuss up-to-date findings on the dopaminergic control of food intake by both the reward-related circuit and the homeostatic hypothalamic system.

Citations

Citations to this article as recorded by

Retracted : Pan‐neuronal knockdown of Ras GTPase‐activating protein 1 alters Drosophila activity and sleep behavior
Francisco Alejandro Lagunas‐Rangel
Archives of Insect Biochemistry and Physiology.2023;[Epub] CrossRef
Maternal Over- and Malnutrition and Increased Risk for Addictive and Eating Disorders in the Offspring
Mathilde C. C. Guillaumin, Daria Peleg-Raibstein
Nutrients.2023; 15(5): 1095. CrossRef
Carving the senescent phenotype by the chemical reactivity of catecholamines: An integrative review
Aleksei G. Golubev
Ageing Research Reviews.2022; 75: 101570. CrossRef
Obesity I: Overview and molecular and biochemical mechanisms
Robert H. Lustig, David Collier, Christopher Kassotis, Troy A. Roepke, Min Ji Kim, Etienne Blanc, Robert Barouki, Amita Bansal, Matthew C. Cave, Saurabh Chatterjee, Mahua Choudhury, Michael Gilbertson, Dominique Lagadic-Gossmann, Sarah Howard, Lars Lind,
Biochemical Pharmacology.2022; 199: 115012. CrossRef
Food preferences and thyroid hormones in children and adolescents with obesity
Daniela Staníková, Lea Krajčovičová, Linda Demková, Petronela Forišek-Paulová, Lucia Slobodová, Eva Vitariušová, Lubica Tichá, Barbara Ukropcová, Juraj Staník, Jozef Ukropec
Frontiers in Psychiatry.2022;[Epub] CrossRef
Dopamine systems and biological rhythms: Let’s get a move on
Qijun Tang, Dina R. Assali, Ali D. Güler, Andrew D. Steele
Frontiers in Integrative Neuroscience.2022;[Epub] CrossRef
Suprachiasmatic to paraventricular nuclei interaction generates normal food searching rhythms in mice
Iwona Olejniczak, Benjamin Campbell, Yuan-Chen Tsai, Shiva K. Tyagarajan, Urs Albrecht, Jürgen A. Ripperger
Frontiers in Physiology.2022;[Epub] CrossRef
THE ROLE OF CIRCADIAN REGULATION OF GHRELIN LEVELS IN PARKINSON’S DISEASE (LITERATURE REVIEW)
Kateryna A. Tarianyk, Nataliya V. Lytvynenko, Anastasiia D. Shkodina, Igor P. Kaidashev
Wiadomości Lekarskie.2021; 74(7): 1750. CrossRef

Diabetes
Continuous Glucose Monitoring in the Hospital: M. Citlalli Perez-Guzman, Trisha Shang, Jennifer Y. Zhang, Donna Jornsay, David C. Klonoff; Endocrinol Metab. 2021;36(2):240-255. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2021.201

12,290 View
543 Download
18 Citations

Abstract PDF PubReader ePub Crossref - TDM

Continuous glucose monitors (CGMs) have suddenly become part of routine care in many hospitals. The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. The use of CGMs to automatically and remotely supplement or replace assisted monitoring of blood glucose by bedside nurses can decrease: the amount of necessary nursing exposure to COVID-19 patients with diabetes; the amount of time required for obtaining blood glucose measurements, and the amount of personal protective equipment necessary for interacting with patients during the blood glucose testing. The United States Food and Drug Administration (FDA) is now exercising enforcement discretion and not objecting to certain factory-calibrated CGMs being used in a hospital setting, both to facilitate patient care and to obtain performance data that can be used for future regulatory submissions. CGMs can be used in the hospital to decrease the frequency of fingerstick point of care capillary blood glucose testing, decrease hyperglycemic episodes, and decrease hypoglycemic episodes. Most of the research on CGMs in the hospital has focused on their accuracy and only recently outcomes data has been reported. A hospital CGM program requires cooperation of physicians, bedside nurses, diabetes educators, and hospital administrators to appropriately select and manage patients. Processes for collecting, reviewing, storing, and responding to CGM data must be established for such a program to be successful. CGM technology is advancing and we expect that CGMs will be increasingly used in the hospital for patients with diabetes.

Citations

Citations to this article as recorded by

The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record
Juan Espinoza, Nicole Y. Xu, Kevin T. Nguyen, David C. Klonoff
Journal of Diabetes Science and Technology.2023; 17(2): 495. CrossRef
Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center
Adrian G. Dumitrascu, Michelle F. Perry, Rebecca J. Boone, Maria P. Guzman, Razvan M. Chirila, Allyson W. McNally, Dorin T. Colibaseanu, Shon E. Meek, Colleen T. Ball, Launia J. White, Ana-Maria Chindris
Endocrine Practice.2023; 29(3): 155. CrossRef
Use of Continuous Glucose Monitors to Manage Type 1 Diabetes Mellitus: Progress, Challenges, and Recommendations
Jared G Friedman, Zulma Cardona Matos, Emily D Szmuilowicz, Grazia Aleppo
Pharmacogenomics and Personalized Medicine.2023; Volume 16: 263. CrossRef
Type 1 Diabetes Overview and Perioperative Management
Grace B. Nelson, Kathryn M. Sumpter
Orthopedic Clinics of North America.2023;[Epub] CrossRef
Real-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience
Samantha R. Spierling Bagsic, Addie L. Fortmann, Rebekah Belasco, Alessandra Bastian, Suzanne Lohnes, Anna Ritko, Haley Sandoval, Mariya Chichmarenko, Emily C. Soriano, Laura Talavera, Athena Philis-Tsimikas
Journal of Diabetes Science and Technology.2023; 17(3): 656. CrossRef
Implementation of Continuous Glucose Monitoring in Critical Care: A Scoping Review
Eileen R. Faulds, Kathleen M. Dungan, Molly McNett
Current Diabetes Reports.2023; 23(6): 69. CrossRef
Clinical use of continuous glucose monitoring in critically ill pediatric patients with diabetic ketoacidosis
Esther Park, Minsun Kim
Diabetes Technology & Therapeutics.2023;[Epub] CrossRef
More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data
Richard M. Bergenstal, Gregg D. Simonson, Lutz Heinemann
Journal of Diabetes Science and Technology.2022; 16(1): 3. CrossRef
Continuous glucose monitoring in the hospital: an update in the era of COVID-19
Chikara Gothong, Lakshmi G. Singh, Medha Satyarengga, Elias K. Spanakis
Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(1): 1. CrossRef
Breakthrough technology for in-hospital glucose monitoring
David Kerr, David Klonoff
The Lancet Diabetes & Endocrinology.2022; 10(5): 304. CrossRef
The Role of the Diabetes Care and Education Specialist in the Hospital Setting

The Science of Diabetes Self-Management and Care.2022; 48(3): 184. CrossRef
Real-Time Monitoring of Blood Parameters in the Intensive Care Unit: State-of-the-Art and Perspectives
Rebecca Bockholt, Shaleen Paschke, Lars Heubner, Bergoi Ibarlucea, Alexander Laupp, Željko Janićijević, Stephanie Klinghammer, Sascha Balakin, Manfred F. Maitz, Carsten Werner, Gianaurelio Cuniberti, Larysa Baraban, Peter Markus Spieth
Journal of Clinical Medicine.2022; 11(9): 2408. CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Stress-Induced Hyperglycemia: Consequences and Management
Deepanjali Vedantam, Devyani S Poman, Lakshya Motwani, Nailah Asif, Apurva Patel, Krishna Kishore Anne
Cureus.2022;[Epub] CrossRef
Hospital Diabetes Meeting 2022
Jingtong Huang, Andrea M. Yeung, Kevin T. Nguyen, Nicole Y. Xu, Jean-Charles Preiser, Robert J. Rushakoff, Jane Jeffrie Seley, Guillermo E. Umpierrez, Amisha Wallia, Andjela T. Drincic, Roma Gianchandani, M. Cecilia Lansang, Umesh Masharani, Nestoras Math
Journal of Diabetes Science and Technology.2022; 16(5): 1309. CrossRef
Staff knowledge, attitudes and practices regarding glycaemic management in adult intensive care units: A national survey
Miao Huang, Ruiqi Yang, Chuanlai Zhang, Xiuni Gan
Nursing in Critical Care.2022;[Epub] CrossRef
Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study
Hun Jee Choe, Eun-Jung Rhee, Jong Chul Won, Kyong Soo Park, Won-Young Lee, Young Min Cho
Diabetes Care.2022; 45(10): 2224. CrossRef
The Devil Is in the Details: Use, Limitations, and Implementation of Continuous Glucose Monitoring in the Inpatient Setting
Rebecca Rick Longo, Renu Joshi
Diabetes Spectrum.2022; 35(4): 405. CrossRef

Diabetes
Cardiorenal Protection in Diabetic Kidney Disease: Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney; Endocrinol Metab. 2021;36(2):256-269. Published online April 19, 2021; DOI: https://doi.org/10.3803/EnM.2021.987

3,892 View
274 Download
7 Citations

Abstract PDF PubReader ePub Crossref - TDM

Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.

Citations

Citations to this article as recorded by

Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD
Ayodele Odutayo, Adeera Levin
Clinical Journal of the American Society of Nephrology.2023; 18(5): 557. CrossRef
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
Endocrinology and Metabolism.2023; 38(1): 43. CrossRef
Management of CKD
Nimrit Goraya, Jennifer D. Moran
Nephrology Self-Assessment Program.2022; 21(2): 146. CrossRef
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Pharmacological Research.2021; 172: 105859. CrossRef
Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression
Ayodele Odutayo, Bruno R. da Costa, Tiago V. Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A. Hincapié, Aquila Akingbade, Myanca Rodrigues, Arnav Agarwal, Bishoy Lawendy, Pakeezah Saadat, Jacob A. Udell, Francesco Cosentino, Peter
Journal of the American Heart Association.2021;[Epub] CrossRef
Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez, José Luis Gorriz
European Endocrinology.2021; 17(2): 84. CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Jorge I. Fonseca-Correa, Ricardo Correa-Rotter
Frontiers in Medicine.2021;[Epub] CrossRef

Bone Metabolism
Operationalizing Treat-to-Target for Osteoporosis: E. Michael Lewiecki; Endocrinol Metab. 2021;36(2):270-278. Published online March 24, 2021; DOI: https://doi.org/10.3803/EnM.2021.970

4,073 View
235 Download
2 Citations

Abstract PDF PubReader ePub Crossref - TDM

Treat-to-target (TTT) for osteoporosis is a concept for individualizing patient treatment decisions that focuses on achieving an acceptable level of fracture risk rather than response to treatment alone. While a response to treatment is essential in order to achieve an acceptable level of risk, it is not necessarily sufficient. Some patients have a good response to treatment yet remain at high level of fracture risk. Since there is no way to directly measure bone strength in patients treated for osteoporosis, a surrogate measurement must be used. Bone mineral density (BMD) is commonly used to select patients for treatment and has emerged as the most useful surrogate for assessing reduction of fracture risk after treatment is started. Recent large meta-regression studies have shown a robust correlation between larger increases in BMD with treatment and greater reductions in fracture risk. Application of TTT for osteoporosis involves assessing fracture risk before starting treatment and initiating treatment with an agent that is most likely to reduce fracture risk to an acceptable level, represented by a target BMD T-score, over a reasonable period of time. This review offers suggestions for implementing TTT for osteoporosis in clinical practice and managing patients who fail or succeed in reaching the target. More study is needed to fully validate the use of TTT for osteoporosis for initiating and modifying treatments to reduce fracture risk.

Citations

Citations to this article as recorded by

Prevalence and Risk Factors of T-Score Spine-Hip Discordance in Patients with Osteoporotic Vertebral Compression Fracture
Byung-Ho Yoon, Ho Won Kang, Su Min Kim, Young Do Koh
Journal of Bone Metabolism.2022; 29(1): 43. CrossRef
Pharmacological treatment of osteoporosis: 2022 update
Yunkyung Jeon, In-Joo Kim
Journal of the Korean Medical Association.2022; 65(4): 241. CrossRef

Obesity and Metabolism
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia: Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lam; Endocrinol Metab. 2021;36(2):279-295. Published online April 19, 2021; DOI: https://doi.org/10.3803/EnM.2021.964

4,762 View
263 Download
8 Citations

Abstract PDF PubReader ePub Crossref - TDM

Patients with familial hypercholesterolemia (FH) are at high or very high risk for cardiovascular disease. Those with heterozygous FH (HeFH) often do not reach low-density lipoprotein cholesterol (LDL-C) targets with statin and ezetimibe therapy, and those with homozygous FH (HoFH) usually require additional lipid-modifying therapies. Drugs that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) offer a novel approach to reduce LDL-C. The monoclonal antibodies, alirocumab and evolocumab, given by subcutaneous injection every 2 or 4 weeks produce reductions in LDL-C of 50% to 60% in patients with HeFH, allowing many of them to achieve their LDL-C goals. Patients with HoFH show a reduced and more variable LDL-C response, which appears to depend on residual LDL receptor activity, and those with receptor-negative mutations may show no response. Inclisiran is a long-acting small interfering RNA therapeutic agent that inhibits the synthesis of PCSK9. Subcutaneous doses of 300 mg can reduce LDL-C by more than 50% for at least 6 months and the responses in HeFH and HoFH patients are similar to those achieved with monoclonal antibodies. These PCSK9 inhibitors are generally well tolerated and they provide a new opportunity for effective treatment for the majority of patients with FH.

Citations

Citations to this article as recorded by

Qualitative and Quantitative Effects of PCSK9 Inhibitors in familial Hypercholesterolemia: a Synthetic Review
Aamina Shakir, Kyle Barron, Kalgi Modi
Current Problems in Cardiology.2023; 48(4): 101550. CrossRef
PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
Juan Vicente-Valor, Xandra García-González, Sara Ibáñez-García, María Esther Durán-García, Ana de Lorenzo-Pinto, Carmen Rodríguez-González, Irene Méndez-Fernández, Juan Carlos Percovich-Hualpa, Ana Herranz-Alonso, María Sanjurjo-Sáez
Biomedicine & Pharmacotherapy.2022; 146: 112519. CrossRef
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
Shakir Ahamad, Shintu Mathew, Waqas A. Khan, Kishor Mohanan
Drug Discovery Today.2022; 27(5): 1332. CrossRef
The biological relevance of PCSK9: when less is better…
Majambu Mbikay, Michel Chrétien
Biochemistry and Cell Biology.2022; 100(3): 189. CrossRef
Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Metabolism.2022; 137: 155327. CrossRef
Homozygous Familial Hypercholesterolemia
Lisa Young, Emily E. Brown, Seth S. Martin
JACC: Case Reports.2022; 4(23): 101666. CrossRef
Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis
Kristina Zubielienė, Gintarė Valterytė, Neda Jonaitienė, Diana Žaliaduonytė, Vytautas Zabiela
Medicina.2022; 58(11): 1665. CrossRef
Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
Eric Bruckert, Sonia Caprio, Albert Wiegman, Min-Ji Charng, Cézar A. Zárate-Morales, Marie T. Baccara-Dinet, Garen Manvelian, Anne Ourliac, Michel Scemama, Stephen R. Daniels
Arteriosclerosis, Thrombosis, and Vascular Biology.2022; 42(12): 1447. CrossRef

Obesity and Metabolism
An Update on Contraception in Polycystic Ovary Syndrome: Seda Hanife Oguz, Bulent Okan Yildiz; Endocrinol Metab. 2021;36(2):296-311. Published online April 15, 2021; DOI: https://doi.org/10.3803/EnM.2021.958

8,198 View
579 Download
9 Citations

Abstract PDF PubReader ePub Crossref - TDM

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in reproductive-aged women, characterized by hyperandrogenism, oligo/anovulation, and polycystic ovarian morphology. Combined oral contraceptives (COCs), along with lifestyle modifications, represent the first-line medical treatment for the long-term management of PCOS. Containing low doses of estrogen and different types of progestin, COCs restore menstrual cyclicity, improve hyperandrogenism, and provide additional benefits such as reducing the risk of endometrial cancer. However, potential cardiometabolic risk associated with these agents has been a concern. COCs increase the risk of venous thromboembolism (VTE), related both to the dose of estrogen and the type of progestin involved. Arterial thrombotic events related to COC use occur much less frequently, and usually not a concern for young patients. All patients diagnosed with PCOS should be carefully evaluated for cardiometabolic risk factors at baseline, before initiating a COC. Age, smoking, obesity, glucose intolerance or diabetes, hypertension, dyslipidemia, thrombophilia, and family history of VTE should be recorded. Patients should be re-assessed at consecutive visits, more closely if any baseline cardiometabolic risk factor is present. Individual risk assessment is the key in order to avoid unfavorable outcomes related to COC use in women with PCOS.

Citations

Citations to this article as recorded by

Current and emerging drug treatment strategies for polycystic ovary syndrome
Nafiye Helvaci, Bulent Okan Yildiz
Expert Opinion on Pharmacotherapy.2023; 24(1): 105. CrossRef
Weighted Gene Co-Expression Network Analysis (WGCNA) Discovered Novel Long Non-Coding RNAs for Polycystic Ovary Syndrome
Roozbeh Heidarzadehpilehrood, Maryam Pirhoushiaran, Malina Binti Osman, Habibah Abdul Hamid, King-Hwa Ling
Biomedicines.2023; 11(2): 518. CrossRef
The mechanism of Leonuri Herba in improving polycystic ovary syndrome was analyzed based on network pharmacology and molecular docking
Mali Wu, Hua Liu, Jie Zhang, Fangfang Dai, Yiping Gong, Yanxiang Cheng
Journal of Pharmacy & Pharmaceutical Sciences.2023;[Epub] CrossRef
Investigation of taste function and eating behavior in women with polycystic ovary syndrome
Sila Cetik, Aylin Acikgoz, Bulent Okan Yildiz
Appetite.2022; 168: 105776. CrossRef
microRNAs and long non‐coding RNAs as biomarkers for polycystic ovary syndrome
Mona Tamaddon, Mostafa Azimzadeh, Seyed Mohammad Tavangar
Journal of Cellular and Molecular Medicine.2022; 26(3): 654. CrossRef
Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients
Min Min, Xiangyan Ruan, Husheng Wang, Jiaojiao Cheng, Suiyu Luo, Zhongting Xu, Meng Li, Alfred Otto Mueck
Gynecological Endocrinology.2022; 38(8): 676. CrossRef
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT
Renyuan Li, Tingting Mai, Siyuan Zheng, Ying Zhang
Archives of Gynecology and Obstetrics.2022; 306(5): 1711. CrossRef
Oral contraceptives and stroke: Foes or friends
Varun Reddy, Megan Wurtz, Shahil H. Patel, Micheline McCarthy, Ami P. Raval
Frontiers in Neuroendocrinology.2022; 67: 101016. CrossRef
Clinical profiling of polycystic ovary syndrome patients in Kashmir population
Ahila Ashraf, Rajesh Singh, Shahnawaz Mir
Matrix Science Pharma.2022; 6(1): 23. CrossRef

Miscellaneous
Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors: Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima; Endocrinol Metab. 2021;36(2):312-321. Published online April 27, 2021; DOI: https://doi.org/10.3803/EnM.2021.1007

3,618 View
225 Download
9 Citations

Abstract PDF PubReader ePub Crossref - TDM

Immune-related adverse events (irAEs) affecting the endocrine glands are among the most frequent irAEs induced by immune checkpoint inhibitors (ICIs) and include hypopituitarism, primary adrenal insufficiency, thyrotoxicosis, hypothyroidism, hypoparathyroidism, and type 1 diabetes mellitus. Since the incidence and clinical features of endocrine irAEs vary according to the ICI used, it is important to understand the characteristics of these irAEs and to manage each one appropriately. Since some endocrine irAEs, including adrenal crisis and diabetic ketoacidosis, are potentially life-threatening, predicting the risk of endocrine irAEs before their onset is critical. Several autoantibodies have been detected in patients who develop endocrine irAEs, among which anti-thyroid antibodies may be predictive biomarkers of thyroid dysfunction. In this review, we describe the clinical features of each endocrine irAE induced by ICIs and discuss their potential biomarkers, including autoantibodies.

Citations

Citations to this article as recorded by

Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report
Marie Okubo, Yuji Hataya, Kanta Fujimoto, Toshio Iwakura, Naoki Matsuoka
Journal of Diabetes Investigation.2023; 14(1): 147. CrossRef
Case Report: A Rising Cause of New-Onset Endocrinopathies After Immunotherapy
Charity Tan, Sarah Hendricks, Kristina Hernandez, Martha Benavides, Rupinderjit Samra
The Journal for Nurse Practitioners.2023; 19(5): 104582. CrossRef
Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline
Xin Zhou, Shintaro Iwama, Tomoko Kobayashi, Masahiko Ando, Hiroshi Arima
The Journal of Clinical Endocrinology & Metabolism.2023;[Epub] CrossRef
Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline
Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Masahiko Ando, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tets
The Journal of Clinical Endocrinology & Metabolism.2022; 107(4): e1620. CrossRef
Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
Ying Zhang, Xiaoling Zhang, Weiling Li, Yunyi Du, Wenqing Hu, Jun Zhao
Human Vaccines & Immunotherapeutics.2022;[Epub] CrossRef
Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle
Agnese Barnabei, Andrea Corsello, Rosa Maria Paragliola, Giovanni Maria Iannantuono, Luca Falzone, Salvatore Maria Corsello, Francesco Torino
Cancers.2022; 14(4): 1057. CrossRef
Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade
Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Xin Zhou, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Masahiro Morise, Taka
The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4115. CrossRef
Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
Fabiana Pani, Yoshinori Yasuda, Sylvie T Rousseau, Kevin C Bermea, Solmaz Roshanmehr, Rulin Wang, Srinivasan Yegnasubramanian, Patrizio Caturegli, Luigi Adamo
Journal for ImmunoTherapy of Cancer.2022; 10(12): e005538. CrossRef
Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers
Anupam Kotwal, Mabel Ryder
Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(5): 517. CrossRef

Special Article

Adrenal gland
Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force: Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan Kwon Jung, Young Seok Cho, Jin Chul Paeng, Jae Hyeon Kim, Ohk-Hyun Ryu, Yumie Rhee, Chong Hwa Kim, Eun Jig Lee; Endocrinol Metab. 2021;36(2):322-338. Published online April 6, 2021; DOI: https://doi.org/10.3803/EnM.2020.908

4,732 View
354 Download
5 Citations

Abstract PDF PubReader ePub Crossref - TDM

Pheochromocytoma and paraganglioma (PPGLs) are rare catecholamine-secreting neuroendocrine tumors but can be life-threatening. Although most PPGLs are benign, approximately 10% have metastatic potential. Approximately 40% cases are reported as harboring germline mutations. Therefore, timely and accurate diagnosis of PPGLs is crucial. For more than 130 years, clinical, molecular, biochemical, radiological, and pathological investigations have been rapidly advanced in the field of PPGLs. However, performing diagnostic studies to localize lesions and detect metastatic potential can be still challenging and complicated. Furthermore, great progress on genetics has shifted the paradigm of genetic testing of PPGLs. The Korean PPGL task force team consisting of the Korean Endocrine Society, the Korean Surgical Society, the Korean Society of Nuclear Medicine, the Korean Society of Pathologists, and the Korean Society of Laboratory Medicine has developed this position statement focusing on the comprehensive and updated diagnosis for PPGLs.

Citations

Citations to this article as recorded by

Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association
A Ram Hong, Ho-Cheol Kang
Endocrinology and Metabolism.2023; 38(2): 175. CrossRef
KSNM60 in Nuclear Endocrinology: from the Beginning to the Future
Chae Moon Hong, Young Jin Jeong, Hae Won Kim, Byeong-Cheol Ahn
Nuclear Medicine and Molecular Imaging.2022; 56(1): 17. CrossRef
Change of Computed Tomography-Based Body Composition after Adrenalectomy in Patients with Pheochromocytoma
Yousun Ko, Heeryoel Jeong, Seungwoo Khang, Jeongjin Lee, Kyung Won Kim, Beom-Jun Kim
Cancers.2022; 14(8): 1967. CrossRef
Evaluation and Management of Bone Health in Patients with Thyroid Diseases: a Position Statement from the Korean Thyroid Association
A Ram Hong, Hwa Young Ahn, Bu Kyung Kim, Seong Hee Ahn, So Young Park, Min-Hee Kim, Jeongmin Lee, Sun Wook Cho, Ho-Cheol Kang
International Journal of Thyroidology.2022; 15(1): 1. CrossRef
Pheochromocytoma with Retroperitoneal Metastasis: A Case Report
建新崔
Advances in Clinical Medicine.2021; 11(05): 2239. CrossRef

Editorial

Diabetes
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors: Chan-Hee Jung; Endocrinol Metab. 2021;36(2):339-341. Published online April 27, 2021; DOI: https://doi.org/10.3803/EnM.2021.203

2,448 View
106 Download

PDF PubReader ePub Crossref - TDM

Original Articles

Clinical Study
Associations of GNAS Mutations with Surgical Outcomes in Patients with Growth Hormone-Secreting Pituitary Adenoma: Hyein Jung, Kyungwon Kim, Daham Kim, Ju Hyung Moon, Eui Hyun Kim, Se Hoon Kim, Cheol Ryong Ku, Eun Jig Lee; Endocrinol Metab. 2021;36(2):342-350. Published online March 23, 2021; DOI: https://doi.org/10.3803/EnM.2020.875

3,146 View
122 Download
1 Citations

Abstract PDF PubReader ePub Crossref - TDM

Background
The guanine nucleotide-binding protein, alpha stimulating (GNAS) gene has been associated with growth hormone (GH)-secreting pituitary adenoma. We investigated the prevalence of GNAS mutations in Korean patients with acromegaly and assessed whether mutation status correlated with biochemical or clinical characteristics.
Methods
We studied 126 patients with acromegaly who underwent surgery between 2005 and 2014 at Severance Hospital. We performed GNAS gene analysis and evaluated age, sex, hormone levels, postoperative biochemical remission, and immunohistochemical staining results of the tumor.
Results
GNAS mutations were present in 75 patients (59.5%). Patients with and without GNAS mutations showed similar age distribution and Knosp classification. The proportion of female patients was 76.5% and 48.0% in the GNAS-negative and GNAS-mutation groups, respectively (P=0.006). In immunohistochemical staining, the GNAS-mutation group showed higher GH expression in pituitary tumor tissues than the mutation-negative group (98.7% vs. 92.2%, P=0.015). Patients with GNAS mutations had higher preoperative insulin-like growth factor-1 levels (791.3 ng/mL vs. 697.0 ng/mL, P=0.045) and lower immediate postoperative basal (0.9 ng/mL vs. 1.0 ng/mL, P=0.191) and nadir GH levels (0.3 ng/mL vs. 0.6 ng/mL, P=0.012) in oral glucose tolerance tests. Finally, the GNAS-mutation group showed significantly higher surgical remission rates than the mutation-negative group, both at 1 week and 6 months after surgical resection (70.7% vs. 54.9%, P=0.011; 85.3% vs. 82.4%, P=0.007, respectively).
Conclusion
GNAS mutations in GH-secreting pituitary tumors are associated with higher preoperative insulin-like growth factor-1 levels and surgical remission rates and lower immediate postoperative nadir GH levels. Thus, GNAS mutation status can predict surgical responsiveness in patients with acromegaly.

Citations

Citations to this article as recorded by

CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma
Haruto Nishida, Yoshihiko Kondo, Takahiro Kusaba, Kazuhiro Kawamura, Yuzo Oyama, Tsutomu Daa, Avaniyapuram Kannan Murugan
PLOS ONE.2023; 18(2): e0281647. CrossRef

Clinical Study
Radioactive Parathyroid Adenomas on Sestamibi Scans: Low Parathyroid Hormone Secretory Potential and Large Volume: Sung Hye Kong, Jung Hee Kim, Sang Wan Kim, Chan Soo Shin; Endocrinol Metab. 2021;36(2):351-358. Published online April 6, 2021; DOI: https://doi.org/10.3803/EnM.2020.823

2,671 View
106 Download

Abstract PDF PubReader ePub Crossref - TDM: Background
We investigated the clinical characteristics of parathyroid adenomas according to radioactivity on ^99mTc-methoxyisobutylisonitrile (^99mTc-MIBI) single-photon emission computed tomography/computed tomography (SPECT/CT) in primary hyperparathyroidism (PHPT) patients.
Methods
The study included 217 patients diagnosed with PHPT from 2000 to 2019 at Seoul National University Hospital who underwent ^99mTc-MIBI SPECT/CT scans. On SPECT/CT, the radioactivity of parathyroid adenomas was measured as the ratio of the mean radioactivity count of the parathyroid adenoma to that of the contralateral thyroid.
Results
Tumors were localized by MIBI scans in 190 patients (MIBI [+] group) and by ultrasound or parathyroid four-dimensional CT in 27 patients (MIBI [–] group). The mean age was 55 years, and mean body mass index was 23.4 kg/m². Patients in the MIBI (+) group had higher parathyroid hormone (iPTH) and lower 25-hydroxy vitamin D levels than those in the MIBI (–) group (168.0 pg/mL [interquartile range, IQR, 111.0 to 250.7] vs. 134.7 pg/mL [IQR, 98.2 to 191.2], P=0.049; 15.4 ng/mL [IQR, 11.1 to 20.8] vs. 21.2 ng/mL [IQR, 13.9 to 24.8], P=0.012, respectively). Patients in the MIBI (+) group had larger tumor volumes, but lower iPTH/volume ratios than those in the MIBI (–) group (1,216.66 [IQR, 513.40 to 2,663.02], 499.82 mm³ [IQR, 167.77 to 1,229.80], P=0.002; 0.18 [IQR, 0.08 to 0.46], 0.40 pg/mL/mm³ [IQR, 0.16 to 1.29], P=0.016, respectively). Adenoma radioactivity was positively correlated with calcium, iPTH, and volume (r=0.180, P=0.020; r=0.208, P=0.006; r=0.288, P<0.001, respectively), but not with iPTH/volume.
Conclusion
Parathyroid adenomas with positive MIBI scans had larger volumes and higher iPTH than adenomas with negative scans, but lower iPTH per unit volume.

Clinical Study
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma: Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim; Endocrinol Metab. 2021;36(2):359-364. Published online March 23, 2021; DOI: https://doi.org/10.3803/EnM.2020.890; Correction in: Endocrinol Metab 2022;37(1):181

4,468 View
173 Download
9 Citations

Abstract PDF PubReader ePub Crossref - TDM

Background
A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.
Methods
Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.
Conclusion
KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.

Citations

Citations to this article as recorded by

Thyroid-Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma in Adults
Yasuhiro Ito, Akira Miyauchi, Makoto Fujishima, Takuya Noda, Tsutomu Sano, Takahiro Sasaki, Taketoshi Kishi, Tomohiko Nakamura
World Journal of Surgery.2023; 47(2): 392. CrossRef
Thyroid FNA cytology: The Eastern versus Western perspectives
Mitsuyoshi Hirokawa, Manon Auger, Chan Kwon Jung, Fabiano Mesquita Callegari
Cancer Cytopathology.2023;[Epub] CrossRef
To Screen or Not to Screen?
Do Joon Park
Endocrinology and Metabolism.2023; 38(1): 69. CrossRef
Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
Endocrinology and Metabolism.2023; 38(1): 93. CrossRef
Thermal ablation for papillary thyroid microcarcinoma located in the isthmus: a study with 3 years of follow-up
Lin Zheng, Fang-yi Liu, Jie Yu, Zhi-gang Cheng, Xiao-ling Yu, Xiao-cong Dong, Zhi-yu Han, Ping Liang
Future Oncology.2022; 18(4): 471. CrossRef
Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000–2018)
Elisa Pasqual, Julie Ann Sosa, Yingxi Chen, Sara J. Schonfeld, Amy Berrington de González, Cari M. Kitahara
Thyroid.2022; 32(4): 397. CrossRef
Management of Low-Risk Thyroid Cancers: Is Active Surveillance a Valid Option? A Systematic Review of the Literature
Renato Patrone, Nunzio Velotti, Stefania Masone, Alessandra Conzo, Luigi Flagiello, Chiara Cacciatore, Marco Filardo, Vincenza Granata, Francesco Izzo, Domenico Testa, Stefano Avenia, Alessandro Sanguinetti, Andrea Polistena, Giovanni Conzo
Journal of Clinical Medicine.2021; 10(16): 3569. CrossRef
Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review
Han-sang Baek, Chai-ho Jeong, Jeonghoon Ha, Ja-Seong Bae, Jeong-soo Kim, Dong-Jun Lim, Chul-Min Kim
Cancer Management and Research.2021; Volume 13: 6721. CrossRef
Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2021; 36(4): 717. CrossRef

First
Prev
Page of 2
Next
Last

Previous issues